Medicine
Dovato 50 mg/300 mg tablet
Dovato 50 mg/300 mg tablet is a prescription medicine containing Dolutegravir and Lamivudine for oral use, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30°C (86°F).
Key facts
- Active ingredient (INN)
- Dolutegravir and Lamivudine
- Brand
- Dovato
- Strength
- 50 mg/300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 1 blister pack
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Store below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR Efavirenz/lamivudine/tenofovir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 April 2019
- Identifiers
- RxCUI 2122519, 2122526DailyMed set ID 68e45422-43ed-4cfb-9356-fae88d14a53aNDC 49702-246Application NDA211994
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 49702-246-13 | ViiV Healthcare | 8 April 2019 |
| 1 blister pack in 1 carton / 30 tablet, film coated in 1 blister pack | 49702-246-33 | ViiV Healthcare | 1 January 2024 |
| 1 blister pack in 1 carton / 14 tablet, film coated in 1 blister pack | 49702-246-62 | ViiV Healthcare | 1 January 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Dolutegravir and Lamivudine is a fixed-dose combination of a hepatitis B virus nucleoside analog reverse transcriptase inhibitor, a human immunodeficiency virus integrase strand transfer inhibitor and a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Dolutegravir and Lamivudine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Dolutegravir and LamivudineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Dovato prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
- Dovato: European public assessment report (EPAR) · European Medicines Agency
Need Dovato 50 mg/300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.